Cargando…

BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 mRNA in XLA patients

Mutations in the Bruton agammaglobulinemia tyrosine kinase (BTK) gene are responsible for X-linked agammaglobulinemia (XLA). Unfolded or misfolded proteins can trigger stress pathways in the endoplasmic reticulum (ER), known as unfolded protein response (UPR). The aim was to clarify the involvement...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teocchi, Marcelo A, Domingues Ramalho, Vanessa, Abramczuk, Beatriz M, D'Souza-Li, Lília, Santos Vilela, Maria Marluce
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578518/ https://www.ncbi.nlm.nih.gov/pubmed/26417435 http://dx.doi.org/10.1002/iid3.57

Ejemplares similares

A mutation in the promoter region of BTK causes atypical XLA
por: Bravo García-Morato, María, et al.
Publicado: (2020)

Transcriptome profiling of monocytes from XLA patients revealed the innate immune function dysregulation due to the BTK gene expression deficiency
por: Mirsafian, Hoda, et al.
Publicado: (2017)

Effective, safe, and sustained correction of murine XLA using a UCOE-BTK promoter-based lentiviral vector
por: Seymour, Brenda J., et al.
Publicado: (2021)

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
por: Kueffer, Lauren E., et al.
Publicado: (2021)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

Clinical characteristics and prenatal diagnosis for 22 families in Henan Province of China with X-linked agammaglobulinemia (XLA) related to Bruton’s tyrosine kinase (BTK) gene mutations
por: Gao, Shanshan, et al.
Publicado: (2020)

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
por: Joseph, Raji E, et al.
Publicado: (2020)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

BTK: sensing pathogenic nucleic acids
por: Lee, Koon-Guan, et al.
Publicado: (2015)

A Fast and Clean BTK Inhibitor
por: Gabizon, Ronen, et al.
Publicado: (2020)

The race to stymie BTK: zanu zings
por: Kapoor, Prashant, et al.
Publicado: (2020)

Targeting Solid Tumors With BTK Inhibitors
por: Uckun, Fatih M., et al.
Publicado: (2021)

BTK, the new kid on the (oncology) block?
por: Grassilli, Emanuela, et al.
Publicado: (2022)

Managing Waldenström’s macroglobulinemia with BTK inhibitors
por: Buske, Christian, et al.
Publicado: (2022)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

P1239: BRUTON TYROSINE KINASE (BTK) PROTEIN DEGRADER BGB-16673 IS LESS APT TO CAUSE, AND ABLE TO OVERCOME VARIABLE BTK RESISTANCE MUTATIONS COMPARED TO OTHER BTK INHIBITORS (BTKI)
por: Feng, Xiaoyu, et al.
Publicado: (2023)

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
por: Nicolson, Phillip L.R., et al.
Publicado: (2018)

Discovery of a potent BTK and IKZF1/3 triple degrader through reversible covalent BTK PROTAC development
por: Yu, Xin, et al.
Publicado: (2022)

PB1912: BTK AND PLCG2 GENE MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH RESISTANCE TO COVALENT BTK INHIBITOR
por: Likold, Ekaterina, et al.
Publicado: (2023)

Differential Evolutionary Wiring of the Tyrosine Kinase Btk
por: Nawaz, Hossain M., et al.
Publicado: (2012)

Ibrutinib and novel BTK inhibitors in clinical development
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Btk Regulates Macrophage Polarization in Response to Lipopolysaccharide
por: Ní Gabhann, Joan, et al.
Publicado: (2014)

Effects of BTK signalling in pathogenic microorganism infections
por: Ye, Bingjue, et al.
Publicado: (2019)

Low-dose Btk inhibitors: an ‘aspirin’ of tomorrow?
por: Payrastre, Bernard, et al.
Publicado: (2021)

Targeting the NLRP3 Inflammasome via BTK
por: Weber, Alexander N. R.
Publicado: (2021)

Current and novel BTK inhibitors in Waldenström’s macroglobulinemia
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2021)

Integrin Signaling Shaping BTK-Inhibitor Resistance
por: Polcik, Laura, et al.
Publicado: (2022)

Limapakgsin ixlilakkaxlan xla pulataman Veracruz xla Ignacio de la Llave
Publicado: (2012)

From identification of the BTK kinase to effective management of leukemia
por: Smith, C I E
Publicado: (2017)

The Development of BTK Inhibitors: A Five-Year Update
por: Tasso, Bruno, et al.
Publicado: (2021)

BTK Inhibitors Impair Platelet-Mediated Antifungal Activity
por: Nasillo, Vincenzo, et al.
Publicado: (2022)

The Immunomodulatory Functions of BTK Inhibition in the Central Nervous System
por: Cao, Tingyu, et al.
Publicado: (2022)

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model
por: Wu, Hong, et al.
Publicado: (2017)

Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
por: Ringheim, Garth E., et al.
Publicado: (2021)

ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
por: Ghoshdastidar, Krishnarup, et al.
Publicado: (2020)

Effects of the Btk-Inhibitors Remibrutinib (LOU064) and Rilzabrutinib (PRN1008) With Varying Btk Selectivity Over Tec on Platelet Aggregation and in vitro Bleeding Time
por: Duan, Rundan, et al.
Publicado: (2021)

Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
por: Arthur, Rachael, et al.
Publicado: (2020)

The Implications of the Cloning of the XLA Gene
por: Flinter, F A, et al.
Publicado: (1993)

Btk expression is controlled by Oct and BOB.1/OBF.1
por: Brunner, Cornelia, et al.
Publicado: (2006)

BTK: a two-faced effector in cancer and tumour suppression
por: Rada, Miran, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u8lruati3lhi2sidun4kak0tl0